AdV-targeted T cells for adenovirus after bone marrow transplant
Part of Infections clinical trials.
This trial tests a custom immune cell treatment (T cells made to recognize adenovirus) for people whose adenovirus infection is not improving or who cannot tolerate standard antiviral medicines after a bone marrow transplant. It aims to help your body control the virus and prevent organ complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had an allogeneic bone marrow transplant and are more than 30 days past it
- You have confirmed adenovirus (HAdV) infection or reactivation based on test results
- You either did not improve after at least 14 days of antiviral treatment, or you have ongoing/worsening symptoms while on antivirals, or you cannot take those antivirals due to allergy or side effects
- Your general function is limited but still manageable (ECOG 0–3, or Karnofsky/Lansky score above the study cutoffs)
- If you can become pregnant—or if you’re a man who could father a child—you agree to effective birth control during the study and for 3 months after
- If you are 14 or older, you can understand and sign the consent form (or assent if younger)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests donor immune cells made to recognize CMV (a virus) or adenovirus, given to help control virus reactivation after a solid organ or bone marrow transplant. It may help reduce ongoing or worsening viral infection when standard antiviral medicines are hard to tolerate or not working well.
This study tests whether specially matched donor T-cells can control “refractory” adenovirus (a virus) that isn’t responding to usual antiviral medicines. It may help if the infection keeps coming back or is already affecting organs like the lungs or bowel.
This trial tests a treatment using specially grown T-cells (a type of immune cell) to fight certain viruses that won't go away with standard medicines. It is for people who have had a stem cell or organ transplant, or who have a weak immune system, and who are struggling with adenovirus, CMV, or EBV infections.
This trial tests a personalized immune cell treatment (CMV-specific T cells) for people whose CMV (a common herpes virus) persists or comes back after a stem cell transplant. It may help your immune system better control CMV when standard antiviral medicines aren’t fully working or can’t be used.
This trial tests a special immune-cell treatment made to fight adenovirus in people whose adenovirus infection keeps coming back or won’t improve after transplant. It may help control infection when standard antiviral medicines are not working or can’t be tolerated.
This trial tests whether adding specially trained immune cells (CTLs) from a related donor to standard treatment helps clear persistent adenovirus or CMV infections after a stem cell transplant. It may be an option if standard antiviral therapy isn't working or causes serious side effects.
Hear when a new Allogeneic Hematopoietic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.